[go: up one dir, main page]

WO2015148415A3 - Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease - Google Patents

Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease Download PDF

Info

Publication number
WO2015148415A3
WO2015148415A3 PCT/US2015/022095 US2015022095W WO2015148415A3 WO 2015148415 A3 WO2015148415 A3 WO 2015148415A3 US 2015022095 W US2015022095 W US 2015022095W WO 2015148415 A3 WO2015148415 A3 WO 2015148415A3
Authority
WO
WIPO (PCT)
Prior art keywords
fll18
treatment
derivatives
generate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/022095
Other languages
French (fr)
Other versions
WO2015148415A2 (en
Inventor
Xiang Ling
Fengzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canget BioTekpharma LLC
Original Assignee
Canget BioTekpharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canget BioTekpharma LLC filed Critical Canget BioTekpharma LLC
Priority to EP15769768.1A priority Critical patent/EP3122754A4/en
Priority to CN201580024524.7A priority patent/CN106715443A/en
Priority to US15/128,977 priority patent/US10344037B2/en
Publication of WO2015148415A2 publication Critical patent/WO2015148415A2/en
Publication of WO2015148415A3 publication Critical patent/WO2015148415A3/en
Anticipated expiration legal-status Critical
Priority to US16/438,025 priority patent/US11084828B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein, are FLl18 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FLl18 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FLl18 platform-derived analogues.
PCT/US2015/022095 2014-03-26 2015-03-24 Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease Ceased WO2015148415A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP15769768.1A EP3122754A4 (en) 2014-03-26 2015-03-24 Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
CN201580024524.7A CN106715443A (en) 2014-03-26 2015-03-24 Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease
US15/128,977 US10344037B2 (en) 2014-03-26 2015-03-24 Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease
US16/438,025 US11084828B2 (en) 2014-03-26 2019-06-11 Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461970572P 2014-03-26 2014-03-26
US61/970,572 2014-03-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/128,977 A-371-Of-International US10344037B2 (en) 2014-03-26 2015-03-24 Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease
US16/438,025 Division US11084828B2 (en) 2014-03-26 2019-06-11 Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease

Publications (2)

Publication Number Publication Date
WO2015148415A2 WO2015148415A2 (en) 2015-10-01
WO2015148415A3 true WO2015148415A3 (en) 2015-12-10

Family

ID=54196553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/022095 Ceased WO2015148415A2 (en) 2014-03-26 2015-03-24 Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease

Country Status (4)

Country Link
US (2) US10344037B2 (en)
EP (1) EP3122754A4 (en)
CN (1) CN106715443A (en)
WO (1) WO2015148415A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (en) 2013-04-30 2016-06-23 オティトピック インク． Dry powder formulation and usage
CN109266740A (en) * 2017-07-14 2019-01-25 中国科学院上海生命科学研究院 For pulmonary cancer diagnosis or the marker and diagnostic reagent of prognosis
KR102507987B1 (en) 2017-09-22 2023-03-21 벡추라 인코포레이티드 Dry Powder Composition with Magnesium Stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN108956563A (en) * 2018-06-21 2018-12-07 东南大学 A method of multi-function metal nano-probe is synthesized with tumour cell biology in situ
WO2020061106A2 (en) 2018-09-17 2020-03-26 Canget Biotekpharma Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease
CN110172461B (en) * 2019-06-03 2023-05-09 上海长征医院 Construction method and application of novel osteosarcoma lung metastasis model
US12268682B2 (en) 2019-07-22 2025-04-08 Canget Bio Tekpharma, LLC Anticancer drug FL118 formulation for treatment of human cancer
WO2021021924A1 (en) * 2019-07-29 2021-02-04 Huang Cai Gu Formulation of antibody based drugs for treating lung cancer by inhalation
CN110628845B (en) * 2019-10-18 2021-12-21 福州大学 Extraction and structure analysis of heparan sulfate/heparin sulfate in oviductus ranae
CN111471742A (en) * 2020-03-26 2020-07-31 山东大学齐鲁医院 Application of DDX21 as a marker for glioma therapy/prognosis
KR102349925B1 (en) * 2020-07-16 2022-01-12 주식회사 피노바이오 A compound containing FL118 drug and immunoconjugates using the same
UY39743A (en) 2021-04-29 2022-11-30 Abbvie Inc ANTI-C-MET ANTIBODY AND DRUG CONJUGATES
CN114767669B (en) * 2022-05-20 2023-07-04 湖南省中医药研究院 P-gp inhibitor and extraction method and application thereof
AU2023359114A1 (en) 2022-10-09 2025-04-24 LaNova Medicines Limited Compounds, compositions and methods
WO2025016467A1 (en) * 2023-07-20 2025-01-23 上海医药集团股份有限公司 Camptothecin compound, antibody drug conjugate, and preparation method therefor and use thereof
US20250312469A1 (en) * 2024-02-06 2025-10-09 Canget Biotekpharma FL118 COMPLEXES FOR TARGETING DDX5, UbE2T or USP2a
US12383633B1 (en) * 2024-10-01 2025-08-12 Zymeron Corporation Injectable formulations of PARP inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191266A1 (en) * 1999-03-31 2009-07-30 Janssen Pharmaceutica N.V. Pregelatinized Starch In A Controlled Release Formulation
US20140066470A1 (en) * 2010-10-29 2014-03-06 Health Research, Inc. Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004260A2 (en) * 1989-09-15 1991-04-04 Research Triangle Institute 10,11-methylenedioxy-20(rs)-camptothecin and 10,11-methylenedioxy-20(s)-camptothecin analogs
GB9410388D0 (en) 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
US5759767A (en) * 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
US20030148996A1 (en) * 2000-03-31 2003-08-07 Joseph Rubinfeld Camptothecin complexes
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191266A1 (en) * 1999-03-31 2009-07-30 Janssen Pharmaceutica N.V. Pregelatinized Starch In A Controlled Release Formulation
US20140066470A1 (en) * 2010-10-29 2014-03-06 Health Research, Inc. Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3122754A4 *
VALENTI ET AL.: "Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells.", MOLECULAR PHARMACOLOGY, vol. 52, no. 1, 1997, pages 82 - 87, XP055240902, Retrieved from the Internet <URL:http://molpharm.aspetjournals.org/content/52/1/82.full.pdf> [retrieved on 20150518] *

Also Published As

Publication number Publication date
EP3122754A4 (en) 2018-02-21
US10344037B2 (en) 2019-07-09
WO2015148415A2 (en) 2015-10-01
US20180170944A1 (en) 2018-06-21
CN106715443A (en) 2017-05-24
US20190367529A1 (en) 2019-12-05
EP3122754A2 (en) 2017-02-01
US11084828B2 (en) 2021-08-10

Similar Documents

Publication Publication Date Title
WO2015148415A3 (en) Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
DOP2017000109A (en) DERIVATIVES OF PHENILTRIAZOL REPLACED WITH HYDROXIALQUIL AND ITS USES
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
WO2015106128A3 (en) Rnai agents modified at the 4&#39;-c-position
WO2016004305A3 (en) Inhibitors of bruton&#39;s tyrosine kinase
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX387235B (en) PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY
JOP20200230A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2015011359A (en) Macrocyclic lrrk2 kinase inhibitors.
EP3337482A4 (en) Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
CL2014001959A1 (en) Compounds derived from substituted phenyl-1h-imidazo [1,2-b] pyrazole; preparation procedure; pharmaceutical composition; and use in the treatment of cancer.
CL2014003325A1 (en) Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer&#39;s disease
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2015012526A (en) Macrocyclic rip2 kinase inhibitors.
MX378607B (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016040814A3 (en) Disulfide polymers and methods of use
MX376087B (en) MACROCYCLIC RIP2 KINASE INHIBITORS.
IL249860A0 (en) Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer
EP3344625A4 (en) Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
BR112016024510A2 (en) medicament, use of brexpiprazole or a pharmaceutically acceptable salt thereof, methods for preventing or treating a substance related disorder and for producing a pharmaceutical composition, pharmaceutical composition, and kit.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15769768

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015769768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015769768

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15769768

Country of ref document: EP

Kind code of ref document: A2